IL33 and pancreatic ductal adenocarcinoma: Studies have indicated that elevating the expression of IL-33 in pancreatic ductal adenocarcinoma (PDAC) cells can diminish the infiltration of TH2 and innate lymphoid cells 2 and enhance the survival rate of PDAC patients.[41] It has also been evidenced that the activation of mast cells can mitigate melanoma metastasis.[42]